Global Animal Anti Infective Medicine Market Size By Type (External Use, Internal Use), By Application (Livestock, Pets), By Region, And Segment Forecasts, 2023 to 2032

The Global Animal Anti-Infective Medicine Market was valued at USD 21.4 billion in 2023 and is projected to reach USD 34.9 billion by 2031, growing at a CAGR of 6.3% during the forecast period from 2023 to 2031. The market is driven by increasing incidences of zoonotic diseases, rising pet adoption, and the growing demand for livestock products. Anti-infective medicines—including antibiotics, antivirals, and antifungals—play a pivotal role in preventing and treating infections in animals, ensuring both animal welfare and food safety.

Governments worldwide are emphasizing animal health regulations, and veterinary healthcare investments are increasing, propelling market expansion. The surge in companion animal ownership and growing awareness of veterinary preventive care are further accelerating demand for anti-infective products.

Drivers

1. Increasing Prevalence of Zoonotic and Infectious Diseases

The surge in animal-borne diseases, including rabies, leptospirosis, and salmonellosis, is a major driver. These conditions necessitate prompt and effective anti-infective treatment to curb disease spread and prevent transmission to humans.

2. Rise in Pet Ownership and Veterinary Healthcare Expenditure

Globally, pet ownership is growing, particularly in urban regions. Owners are increasingly inclined to invest in preventive healthcare, including anti-infective medications, to ensure their pets' longevity and quality of life.

3. Livestock Industry Growth and Demand for Animal Protein

The escalating demand for meat, milk, and eggs is fueling intensive livestock farming practices, where anti-infective medicines are used both therapeutically and prophylactically to ensure herd health and productivity.

Restraints

1. Antimicrobial Resistance (AMR) Concerns

The overuse and misuse of antibiotics in veterinary care have led to mounting concerns over antimicrobial resistance. Regulatory restrictions and consumer scrutiny are challenging the long-term use of certain classes of anti-infectives.

2. Regulatory Stringency and Drug Approval Delays

Strict guidelines for veterinary drug approvals, especially in regions like North America and Europe, can delay product launches, increasing compliance costs for manufacturers.

Opportunity

1. Innovation in Targeted and Sustainable Anti-Infective Therapies

Biotechnology advancements and increased R&D funding are enabling the development of next-generation anti-infective drugs with targeted action and minimal resistance risks.

2. Emerging Markets Expansion

The rise in disposable incomes, livestock populations, and pet adoption in regions such as Asia-Pacific, Latin America, and parts of Africa present untapped growth opportunities for animal health product manufacturers.

Market by System Type Insights

Based on system type, the Antibiotics segment dominated the market in 2023, owing to its widespread use in livestock and companion animals. Despite rising resistance issues, antibiotics remain the first-line treatment for bacterial infections. However, the Antiparasitic and Antiviral segments are expected to register faster growth, driven by increasing awareness and targeted disease control efforts.

Market by End-use Insights

The Livestock segment—especially poultry and cattle—accounted for the largest market share in 2023. These animals are critical for food production, and maintaining their health is a global priority. Meanwhile, the Companion Animals segment is projected to grow rapidly due to increasing urbanization, human-animal bonding, and advances in pet healthcare services.

Market by Regional Insights

North America led the global market in 2023, driven by high veterinary healthcare spending, advanced animal healthcare infrastructure, and active regulatory support. Asia-Pacific, however, is expected to witness the highest CAGR during the forecast period, propelled by growing animal healthcare awareness, rising meat consumption, and increased veterinary investments across India, China, and Southeast Asia.

Competitive Scenario

Key players in the Global Animal Anti-Infective Medicine Market include:

Zoetis Inc.

Boehringer Ingelheim

Merck Animal Health

Elanco Animal Health

Ceva Santé Animale

Virbac

Vetoquinol S.A.

Dechra Pharmaceuticals

Bayer Animal Health

Norbrook Laboratories

These companies are focusing on expanding their product portfolios, investing in biologics and targeted therapies, and entering strategic partnerships with research institutions and distributors.

Scope of Work – Global Animal Anti-Infective Medicine Market

Key Market Developments

2023: Zoetis launched a new long-acting antibiotic for swine and cattle with improved compliance and residue-free characteristics.

2024: Merck Animal Health expanded its vaccine production facility to include a broader portfolio of anti-infective solutions for companion animals.

2025: Elanco partnered with a biotech firm to co-develop mRNA-based antivirals targeting emerging zoonotic infections in livestock.

FAQs

1) What is the current market size of the Global Animal Anti-Infective Medicine Market?

The market was valued at USD 21.4 billion in 2023.

2) What is the major growth driver of the Global Animal Anti-Infective Medicine Market?

The major growth driver is the increasing prevalence of zoonotic and infectious diseases.

3) Which is the largest region during the forecast period in the Global Animal Anti-Infective Medicine Market?

North America held the largest market share in 2023, while Asia-Pacific is projected to grow at the highest rate.

4) Which segment accounted for the largest market share in Global Animal Anti-Infective Medicine Market?

The Livestock segment, particularly poultry and cattle, accounted for the largest market share in 2023.

5) Who are the key market players in the Global Animal Anti-Infective Medicine Market?

Key players include Zoetis, Merck Animal Health, Elanco, Boehringer Ingelheim, and Virbac.